Literature DB >> 24715656

The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Timothy Charles Ryken1, Nafi Aygun, Johnathan Morris, Marin Schweizer, Rajeshwari Nair, Cassandra Spracklen, Steven N Kalkanis, Jeffrey J Olson.   

Abstract

QUESTION: Which imaging techniques most accurately differentiate true tumor progression from pseudo-progression or treatment related changes in patients with previously diagnosed glioblastoma? TARGET POPULATION: These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process. RECOMMENDATIONS LEVEL II: Magnetic resonance imaging with and without gadolinium enhancement is recommended as the imaging surveillance method to detect the progression of previously diagnosed glioblastoma. LEVEL II: Magnetic resonance spectroscopy is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma. LEVEL III: The routine use of positron emission tomography to identify progression of glioblastoma is not recommended. LEVEL III: Single-photon emission computed tomography imaging is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24715656     DOI: 10.1007/s11060-013-1330-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  87 in total

1.  Extent of tumor-brain interface: a new tool to predict evolution of malignant gliomas.

Authors:  C A Valéry; B Marro; O Boyer; M Duyme; K Mokhtari; C Marsault; D Klatzmann; J Philippon
Journal:  J Neurosurg       Date:  2001-03       Impact factor: 5.115

2.  3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging.

Authors:  Yuka Yamamoto; Terence Z Wong; Timothy G Turkington; Thomas C Hawk; David A Reardon; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2006 Nov-Dec       Impact factor: 3.488

3.  Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

Authors:  J C Easaw; W P Mason; J Perry; N Laperrière; D D Eisenstat; R Del Maestro; K Bélanger; D Fulton; D Macdonald
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

Review 4.  Advances in PET imaging of brain tumors: a referring physician's perspective.

Authors:  Gregorio J Petrirena; Serge Goldman; Jean-Yves Delattre
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

5.  Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.

Authors:  Craig J Galbán; Thomas L Chenevert; Charles R Meyer; Christina Tsien; Theodore S Lawrence; Daniel A Hamstra; Larry Junck; Pia C Sundgren; Timothy D Johnson; Stefanie Galbán; Judith S Sebolt-Leopold; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2011-04-28       Impact factor: 12.531

Review 6.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Authors:  Dieta Brandsma; Lukas Stalpers; Walter Taal; Peter Sminia; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

7.  2-[C-11]thymidine imaging of malignant brain tumors.

Authors:  J F Eary; D A Mankoff; A M Spence; M S Berger; A Olshen; J M Link; F O'Sullivan; K A Krohn
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

8.  Application of positron emission tomography to neurological oncology.

Authors:  H W Chin; A H Fruin; J M Bertoni; M P Frick; C Y Shiue; G McClellan; D Lefkowitz; C Taylon; B M Boman
Journal:  Nebr Med J       Date:  1991-03

9.  Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury.

Authors:  Qing-Shi Zeng; Chuan-Fu Li; Kai Zhang; Hong Liu; Xiao-Shui Kang; Jun-Hui Zhen
Journal:  J Neurooncol       Date:  2007-02-14       Impact factor: 4.130

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

View more
  30 in total

1.  Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.

Authors:  Guido H Jajamovich; Chandni R Valiathan; Razvan Cristescu; Sangeetha Somayajula
Journal:  J Neurooncol       Date:  2016-07-08       Impact factor: 4.130

2.  ²³Na-MRI of recurrent glioblastoma multiforme after intraoperative radiotherapy: technical note.

Authors:  Stefan Haneder; Frank A Giordano; Simon Konstandin; Stefanie Brehmer; Karen A Buesing; Peter Schmiedek; Lothar R Schad; Frederik Wenz; Stefan O Schoenberg; Melissa M Ong
Journal:  Neuroradiology       Date:  2014-11-27       Impact factor: 2.804

3.  Analyzing magnetic resonance imaging data from glioma patients using deep learning.

Authors:  Bjoern Menze; Fabian Isensee; Roland Wiest; Bene Wiestler; Klaus Maier-Hein; Mauricio Reyes; Spyridon Bakas
Journal:  Comput Med Imaging Graph       Date:  2020-12-02       Impact factor: 4.790

4.  Clinical practice guidelines in the AANS/CNS Section on Tumors: past, present and future directions.

Authors:  Mark E Linskey; Jeffrey J Olson; Laura S Mitchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2014-08-01       Impact factor: 4.130

5.  Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460].

Authors:  Karl-Josef Langen; Jörg C Tonn; Michael Weller; Norbert Galldiks
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

6.  Neuro-oncology: Amino acid PET for brain tumours - ready for the clinic?

Authors:  Karl-Josef Langen; Colin Watts
Journal:  Nat Rev Neurol       Date:  2016-06-10       Impact factor: 42.937

Review 7.  MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy.

Authors:  Chloé Najac; Sabrina M Ronen
Journal:  Top Magn Reson Imaging       Date:  2016-10

8.  Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter.

Authors:  Hatef Mehrabian; Wilfred W Lam; Sten Myrehaug; Arjun Sahgal; Greg J Stanisz
Journal:  J Neurooncol       Date:  2018-03-28       Impact factor: 4.130

Review 9.  An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013.

Authors:  Sophie Pietschmann; André O von Bueren; Guido Henke; Michael Josef Kerber; Rolf-Dieter Kortmann; Klaus Müller
Journal:  J Neurooncol       Date:  2014-08-27       Impact factor: 4.130

10.  MRI during radiotherapy of glioblastoma : Does MRI allow for prognostic stratification?

Authors:  C Leitzen; T Wilhelm-Buchstab; L C Schmeel; S Garbe; S Greschus; T Müdder; S Oberste-Beulmann; B Simon; H H Schild; H Schüller
Journal:  Strahlenther Onkol       Date:  2016-06-03       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.